Mystakidou Kyriaki, Katsouda Emmanuela, Parpa Efi, Tsiatas Marinos L, Vlahos Lambros
Department of Radiology, University of Athens, Athens, Greece.
Am J Hosp Palliat Care. 2005 May-Jun;22(3):228-32. doi: 10.1177/104990910502200313.
Breakthrough pain is a transitory flare of pain occurring in most cancer patients against a background of otherwise controlled persistent pain. Treatment of breakthrough pain is a challenging phenomenon. Oral transmucosal fentanyl citrate (Actiq, Cephalon, Inc, West Chester, PA), a new opioid formulation with a unique delivery system, reflects the characteristics of breakthrough pain (rapid onset of action and short duration), making it an effective treatment for cancer patients who already receive opioids and experience flares of pain. This review article aims to present the role of oral transmucosal fentanyl citrate in the management of breakthrough pain in cancer patients. In particular, it is going to discuss the synthesis, clinical pharmacology, pharmacokinetic and pharmacodynamic properties, toxicity, and clinical efficacy of this novel agent.
爆发性疼痛是大多数癌症患者在其他方面持续性疼痛得到控制的背景下出现的短暂性疼痛发作。爆发性疼痛的治疗是一个具有挑战性的现象。口服黏膜芬太尼柠檬酸盐（Actiq，Cephalon公司，宾夕法尼亚州韦斯特切斯特）是一种具有独特给药系统的新型阿片类药物制剂，体现了爆发性疼痛的特点（起效迅速、持续时间短），使其成为已经接受阿片类药物治疗且经历疼痛发作的癌症患者的有效治疗方法。这篇综述文章旨在阐述口服黏膜芬太尼柠檬酸盐在癌症患者爆发性疼痛管理中的作用。特别是，它将讨论这种新型药物的合成、临床药理学、药代动力学和药效学特性、毒性以及临床疗效。
